Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: Involvement of vascular endothelial growth factor-C

Transplantation Proceedings

Volumn 43, Issue 7, 2011, Pages 2747-2754

  Zhou, S ^a,b   Tan, C ^a   Dai, Z ^a   Zhu, H ^b   Xu, M ^a   Zhou, Z ^a,b   Wang, W ^a,b   Zhao, Y ^a   Fu, X ^a   Zhou, J ^a,b   Fan, J ^a,b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; TACROLIMUS; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA PRIMERS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; TACROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 80052775556     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.06.040     Document Type: Article

References (36)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43
2. L. Bolondi, S. Sofia, and S. Siringo Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis Gut 48 2001 251
3. D.S. Bai, Z. Dai, and J. Zhou Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma Hepatology 49 2009 460
4. M.A. Zimmerman, R.M. Ghobrial, and M.J. Tong Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators Arch Surg 143 2008 182
5. V. Mazzaferro Results of liver transplantation: with or without Milan criteria? Liver Transpl 13 2007 S44
6. S. Roayaie, J.D. Schwartz, and M.W. Sung Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis Liver Transpl 10 2004 534
7. J.Y. Leung, A.X. Zhu, and F.D. Gordon Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study Liver Transpl 10 2004 1343
8. M. Shimoda, R.M. Ghobrial, and I.C. Carmody Predictors of survival after liver transplantation for hepatocellular carcinoma associated with hepatitis C Liver Transpl 10 2004 1478
9. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
10. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530
11. M. Maluccio, V. Sharma, and M. Lagman Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression Transplantation 76 2003 597
12. T. Ogawa, H. Tashiro, and Y. Miyata Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model Am J Transplant 7 2007 347
13. D. Datta, A.G. Contreras, and A. Basu Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells Cancer Res 69 2009 8902
14. M. Vivarelli, R. Bellusci, and A. Cucchetti Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 2002 1746
15. M. Schwartz, M. Konstadoulakis, and S. Roayaie Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl 11 2005 494
16. M. Vivarelli, A. Cucchetti, and F. Piscaglia Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression Liver Transpl 11 2005 497
17. D. Semela, A.C. Piguet, and M. Kolev Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 2007 840
18. R. Yang, F.J. Rescorla, and C.R. Reilly A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation J Surg Res 52 1992 193
19. Y. He, K. Kozaki, and T. Karpanen Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling J Natl Cancer Inst 94 2002 819
20. J.L. Su, P.C. Yang, and J.Y. Shih The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells Cancer Cell 9 2006 209
21. Q. Gao, X.Y. Wang, and S.J. Qiu Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 2009 971
22. Q. Gao, S.J. Qiu, and J. Fan Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection J Clin Oncol 25 2007 2586
23. G. Ercolani, G.L. Grazi, and M. Ravaioli The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy Ann Surg 239 2004 202
24. H.C. Sun, P.Y. Zhuang, and L.X. Qin Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy J Surg Oncol 96 2007 37
25. Z. Xiang, Z. Zeng, and Z. Tang Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome Cancer J 15 2009 519
26. D. Witte, A. Thomas, and N. Ali Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma Anticancer Res 22 2002 1463
27. K. Akagi, Y. Ikeda, and M. Miyazaki Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues Br J Cancer 83 2000 887
28. I. Hashimoto, J. Kodama, and N. Seki Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer Br J Cancer 85 2001 93
29. M. Skobe, T. Hawighorst, and D.G. Jackson Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Nat Med 7 2001 192
30. K. Plate From angiogenesis to lymphangiogenesis Nat Med 7 2001 151
31. Z. Gombos, X. Xu, and C.S. Chu Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix Clin Cancer Res 11 2005 8364
32. T.P. Padera, A. Kadambi, and E. di Tomaso Lymphatic metastasis in the absence of functional intratumor lymphatics Science 296 2002 1883
33. R. Masood, A. Kundra, and S. Zhu Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops Int J Cancer 104 2003 603
34. T. Hoshida, N. Isaka, and J. Hagendoorn Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications Cancer Res 66 2006 8065
35. V. Kirkin, R. Mazitschek, and J. Krishnan Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2 Eur J Biochem 268 2001 5530
36. B. Pytowski, J. Goldman, and K. Persaud Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody J Natl Cancer Inst 97 2005 14